Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of <i>Cryptosporidium hominis</i> by clinical metagenomics in stool samples from an outbreak of diarrhoea among British military personnel in Kenya.

BMJ military health·2026
Same author

Long-Term Efficacy of Disinfectants Against Ebola Virus and Nipah Virus for Use in Containment Level 4 Laboratories.

Viruses·2026
Same author

Sex Differences and Oxidative Stress in Cardiovascular Disease.

Physiology (Bethesda, Md.)·2026
Same author

The Therapeutic Potential for Steroid Treatment Strategies in the Treatment of Murine Venezuelan Equine Encephalitis Virus (VEEV) Infection.

Viruses·2026
Same author

Whole Genome Amplification of Microbial DNA from Host-Depleted Clinical Samples.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Development of a clinical metagenomics workflow for the diagnosis of wound infections.

BMC medical genomics·2024

Related Experiment Video

Updated: Apr 7, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K

Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type.

Sophie J Smither1, Simon A Weller2, Amanda Phelps2

  • 1CBR Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom sjsmither@dstl.gov.uk.

Journal of Clinical Microbiology
|July 17, 2015
PubMed
Summary

Buffer AVL alone does not reliably inactivate Ebola virus (EBOV). Combining Buffer AVL with ethanol or heat ensures complete EBOV inactivation and preserves RNA quality for diagnostic testing.

More Related Videos

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples
06:59

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples

Published on: June 30, 2018

7.9K
Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment
08:22

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Published on: July 19, 2017

10.9K

Related Experiment Videos

Last Updated: Apr 7, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K
Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples
06:59

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples

Published on: June 30, 2018

7.9K
Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment
08:22

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Published on: July 19, 2017

10.9K

Area of Science:

  • Virology
  • Molecular Biology
  • Public Health

Background:

  • Rapid inactivation of Ebola virus (EBOV) is critical for safe and efficient high-throughput testing in resource-limited settings.
  • Current diagnostic protocols require reliable methods to inactivate EBOV in clinical samples before analysis.

Purpose of the Study:

  • To evaluate the efficacy of Buffer AVL, a reagent for RNA extraction, in inactivating EBOV in diagnostic samples.
  • To assess alternative and combined inactivation methods for EBOV in clinical matrices.

Main Methods:

  • EBOV inactivation was tested using Buffer AVL, ethanol, heat, and combinations thereof in spiked marmoset serum and murine blood.
  • Viral infectivity was assessed via cell culture, and RNA integrity was evaluated using PCR.

Main Results:

  • Buffer AVL alone failed to inactivate EBOV in 67% of samples.
  • Ethanol and heat treatments alone also showed limited or no EBOV inactivation.
  • Combined treatments of Buffer AVL with ethanol or heat achieved 100% EBOV inactivation without compromising RNA quality.

Conclusions:

  • Buffer AVL is not sufficient for reliable EBOV inactivation in diagnostic samples.
  • Combined Buffer AVL and ethanol or heat treatments provide a robust method for EBOV inactivation and RNA preservation.